However, IDH1 is more common in low-grade gliomas, while IDH2 mutations are more prevalent in hematologic malignancies. Chan et al. discovered that patients with IDH1/2 mutation are more likely to respond to BCL2 inhibition by venetoclax [13]. Here, BCL2 is linked to central nervous system cancer.